Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 2/20 | 0.61 |
| ▸ | TRPV4 | Q9HBA0 | 13/20 | 0.45 |
| ▸ | TACR2 | P21452 | 5/20 | 0.44 |
| ▸ | TACR3 | P29371 | 5/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648673 | 0.84 | GCGR (0.56) | GCGRTRPV4TACR2TACR3 | |
| SCHEMBL2649498 | 0.83 | GCGR (0.67) | GCGR | |
| SCHEMBL2647513 | 0.77 | GCGR (1.00) | GCGR | |
| SCHEMBL2648836 | 0.76 | GCGR (0.77) | GCGR | |
| SCHEMBL2647230 | 0.76 | GCGR (0.80) | GCGR | |
| SCHEMBL6565362 | 0.75 | GCGR (0.79) | GCGR | |
| SCHEMBL27525551 | 0.75 | GCGR (0.79) | GCGR | |
| SCHEMBL2646545 | 0.74 | GCGR (0.77) | GCGR | |
| SCHEMBL2649565 | 0.74 | GCGR (0.65) | GCGR | |
| SCHEMBL2654771 | 0.72 | GCGR (0.67) | GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| US-6218431-B1 | GLUCAGON RECEPTOR ANTAGONISTS FOR THERAPY OF DIABETES AND CONDITIONS ASSOCIATED WITH DIABETES | BAYER CORPORATION | 2001-04-17 | — | — | US | disclosed |
| EP-0934274-A1 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | Bayer Corporation (US) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |
| WO-1998004528-A2 | SUBSTITUTED PYRIDINES AND BIPHENYLS AS ANTI-HYPERCHOLESTERINEMIC, ANTI-HYPERLIPOPROTEINEMIC AND ANTI-HYPERGLYCEMIC AGENTS | BAYER CORPORATION (US) | 1998-02-05 | — | — | WO | disclosed |